Please login to the form below
drug side effects
This page shows the latest drug side effects news and features for those working in and with pharma, biotech and healthcare.
FDA narrows label for Biogen’s Aduhelm to only include mild forms of Alzheimer’s disease
s common and potentially serious side effects.”. ... This reflects a discount of 85-95% on the drug’s current list price.
Latest news
-
FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
If Aduhelm fails to prove its clinical benefit for patients, the FDA can choose to withdraw the approval of the drug. ... s common and potentially serious side effects,” ICER said in a statement.
-
MSD launches antibiotic combo Recarbrio in UK
The result was particularly significant, given that colistin is often reserved as a ‘last-line’ therapeutic for Gram-negative infections, although the drug can have significant side-effects including kidney damage. ... According to the World Health
-
Sobi’s Gamifant receives final rejection from CHMP for primary HLH
drug’s side effects. ... Gamifant was approved by the US Food and Drug Administration (FDA) for the treatment of primary HLH in November 2018.
-
AbbVie signs immunotherapy pact with I-Mab worth $2bn
In addition, I-Mab will receive a milestone payment of $20m based on results from phase 1 studies of the drug. ... Lemzoparlimab is designed to minimise binding to normal red blood cells while also demonstrating strong anti-tumour activity, which helps
-
Nektar’s opioid analgesic slammed with FDA panel rejection
High levels of euphoric side-effects from opioid medications have lead to abuse and addiction, which has caused a healthcare crisis to erupt across the US. ... Nektar’s drug avoids these side-effects because – according to the company – its
FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
MSD launches antibiotic combo Recarbrio in UK
Sobi’s Gamifant receives final rejection from CHMP for primary HLH
AbbVie signs immunotherapy pact with I-Mab worth $2bn
Nektar’s opioid analgesic slammed with FDA panel rejection
More from news
Approximately 1 fully matching, plus 112 partially matching documents found.
Latest Intelligence
-
Where next in Alzheimer’s disease R&D?
Much of this research centred on improving the selectivity of compounds so that they hit the target, M1, without also interacting with similar receptors linked to the intolerable side effects. ... Meanwhile, Karuna Pharmaceuticals has raised $42m to
-
Redirecting your patient strategy
But when people are dealing with their condition for so long, it is important that you understand how they're actually managing it, how they're using the drug.”. ... These new companies have developed novel business models based on sharing the data and
-
Choices, choices: the rapidly evolving HIV treatment landscape
IIs are more potent, with fewer side effects and drug interactions and the top reason for prescribing them is their good tolerability profile. ... As patients differ so do their barriers to adherence, whether this be complexity of the dosing regimen,
-
Patients First
to their thoughts on the impact of drug side effects, these are all areas that pharma is already actively engaged with at some level.
-
Oncology drugs under AMNOG: part two
The G-BA assesses drugs on four criteria: mortality; morbidity (for example, symptom improvement); quality of life; and adverse events (toxicity and side effects). . ... A natural question to ask is how the benefit finding impacts the final price of a
Where next in Alzheimer’s disease R&D?
Redirecting your patient strategy
Choices, choices: the rapidly evolving HIV treatment landscape
Patients First
Oncology drugs under AMNOG: part two
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
My MS journey: one patient's search for innovation
I’ve also seen a neuro-urologist who deals with bladder problems. The problem is, each specialist may give you a drug which can have unpleasant side effects, causing another layer
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- Live Webinar: Artificial Intelligence for Improving Patient Outcomes & Operational Efficiency
- CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- AstraZeneca chooses Ireland for $360m manufacturing site
- Building the perfect behaviour-change buffet
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- The transatlantic opioid crisis
- WHO to test three more potential COVID-19 treatments
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
PMHub
Madmicrobe Studios - Medical Animation
MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
